



Andrographolide Increases Cell Viability and Proliferation of Human Umbilical Cord-Derived Mesenchymal Stem Cells

Mintra Kaewkittikhun^{1,2}, Naruphong Phunikom^{1,2}, Pakpoom Kheolamai^{1,2}, Sirikul Manochantr^{1,2}, Chairat Tantrawatpan^{1,2}, Duangrat Tantikanlayaporn^{1,2,*}

¹*Division of Cell Biology, Faculty of Medicine, Thammasat University, Pathum Thani 12120, Thailand*

²*Center of Excellence in Stem Cell Research, Thammasat University, Pathum Thani 12120, Thailand*

Received 3 October 2019; Received in revised form 28 April 2020

Accepted 16 July 2020; Available online 6 September 2021

ABSTRACT

The decline in the number of bone marrow-derived human mesenchymal stem cells (BM-hMSCs) is one important factor that contributes to many degenerative diseases. BM-hMSCs have been extensively studied for research and clinical applications, but the invasiveness of the relevant procedure, and the fact that their number declines with age are of concern. Recently, human umbilical cord-derived MSCs (UC-hMSCs) have received more interest because they can be obtained easily by a non-invasive procedure. However, in vitro expansion is required for clinical use. This study aimed to search for new safe agents able to increase cell growth of UC-hMSCs. Therefore, we examined the proliferative effect of Andrographolide on UC-hMSCs. The characteristics of UC-hMSCs were verified before use. In this study, UC-hMSCs were cultured in a growth medium and treated with Andrographolide (0.01-50 μ M) for 24-120 hours. At the indicated time point, cells were collected for evaluating cell viability and cell proliferation by MTT and BrdU assays, respectively. UC-hMSCs have shown characteristics of MSCs matching the criteria that can be used for further studies. After the UC-hMSCs were exposed to Andrographolide, at concentrations of 0.01-5 μ M for 24-120 hours, it was found that Andrographolide at 0.01-10 μ M had no toxicity to UC-hMSCs. Moreover, Andrographolide at 0.01-10 μ M increased the proliferation of UC-hMSCs after treatment for 24-120 hours. In conclusion, this is the first report demonstrating that Andrographolide increases the expansion of UC-hMSCs in culture. These results suggest that Andrographolide may be a good candidate for further development as an alternative agent for increasing the number of MSC in therapeutic applications treating degenerative diseases.

Keywords: Andrographolide; Cell viability; Cell proliferation; Umbilical cord-derived mesenchymal stem cell

1. Introduction

A decline in the number of bone marrow-derived mesenchymal stem cells (BM-hMSCs) has been shown to be an important factor contributing to many degenerative diseases such as osteoporosis, osteoarthritis, Alzheimer's, and Parkinson's diseases [1]. To date, MSCs have been isolated from many different tissues, including bone marrow [2], adipose [3], cartilage, muscle, as well as gestational tissues such as umbilical cord and placenta [4-5]. For *in vitro* expansion, the minimum criteria to define human MSC were suggested in 2006 by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy (ISCT) [6]. First, an MSC must be plastic adherent when maintained in standard culture conditions. Second, MSCs must express CD105, CD73, and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR surface molecules. Third, MSCs must be competent for *in vitro* differentiation into osteoblasts, chondroblasts, and adipocytes under standard culture conditions. Although bone marrow is the most frequently practiced location from which MSCs are harvested by standard operation procedure and with high success rate [7-8], cell harvesting requires an invasive procedure and the amount of BM is limited [9]. Therefore, *in vitro* cell expansion of BM-hMSCs has become a great restriction for their clinical use, resulting in alternative sources receiving more exploration and research. Umbilical cord-derived mesenchymal stem cells (UC-hMSCs), an alternative source for MSC isolation, can be acquired via non-invasive procedure and can be easily cultured, making them potentially superior candidates for use [10]. Although UC-hMSCs can be obtained in larger quantities than BM-MSCs, *in vitro* expansion is required for clinical research and application. This study aimed to explore new safe agents that are able to increase the cell growth of UC-hMSCs. Andrographolide is one popular

compound that possesses several pharmacological activities including anti-inflammatory [11] and anti-oxidative properties [12]. To date, it has been widely used clinically for treating fever, inflammation, diarrhea, and other infectious diseases without any side effects [13]. Therefore, this study was interested in examining the effect of Andrographolide on *in vitro* UC-hMSC viability and cell proliferation.

2. Materials and Methods

2.1 Subject

This study was approved by the Human Ethics Committee of Thammasat University No.1 (Faculty of Medicine; MTU-EC-DS-6-146-61) in accordance with the Declaration of Helsinki, the Belmont Report, and ICH-GCP. The umbilical cord tissues were obtained from full-term pregnancies after labor and all donors gave written informed consent.

2.2 Isolation and culture of UC-hMSCs

The umbilical cord tissues were cut into small pieces and incubated with 0.25% (w/v) trypsin-EDTA (GIBCO™, Invitrogen Corporation, USA) for 30 minutes at 37°C. The pieces were then washed twice with PBS and cultured in DMEM+10% (v/v) FBS (GIBCO™, Invitrogen Corporation, USA) in a 25 cm² culture flask (Corning, USA). Cells were cultured at 37°C. For the removal of non-adherent cells, cultured media were changed every 3 days. The adherent cells were further cultured until colonies of fibroblast-like cells were obtained. For expansion, the cells were sub-cultured using 0.25% trypsin-EDTA. The morphology of hMSCs was observed and photographed under an inverted microscope (Nikon Eclipse Ts2R, Japan).

2.3 Immunophenotypical characterization of UC-hMSCs

The phenotype of the UC-MSCs was evaluated by flow cytometry

(FACScalibur™, Becton Dickinson, USA) and CellQuest® software (Becton Dickinson, USA). Native third to sixth passage UC-MSCs were trypsinized using 0.25% trypsin-EDTA and suspended in PBS. Cells were incubated with fluorochrome-labeled mouse anti-human monoclonal antibodies: anti-CD45-FITC (Bio Legend, USA), anti-CD34-PE (Biolegend, USA), anti-CD90-FITC (Bio Legend, USA), anti-CD73-PE (Bio Legend, USA), and anti-CD105-PE (BD Bioscience, USA) for 30 minutes at 4°C in the dark. After incubating with the antibodies, cell pellets were washed twice with PBS and fixed with 1% (w/v) paraformaldehyde in PBS.

2.4 Adipogenic and osteogenic and differentiation ability of UC-hMSCs

UC-MSCs (passages 3rd-6th) were used to evaluate their adipogenic and osteogenic differentiation potentials. Cells at a density of 1×10^4 cells/cm² were cultured in growth medium (10%FBS+DMEM). For adipogenic differentiation, after cells reached 70% confluence, the medium was replaced with adipogenic medium consisting of DMEM (high glucose) supplemented with 10% FBS, 0.5 mM isobutylmethylxanthine, 1 μM dexamethasone, 5 μg/ml insulin solution, and 100 μM indomethacin (Sigma-Aldrich; Merck KGaA). The adipogenic medium was changed twice weekly, and then after 28 days, the generation of lipid droplets was revealed by Oil Red O staining (Sigma-Aldrich; Merck KGaA). For osteogenic differentiation, after cells reached ~80% confluence, the medium was changed to the osteogenic differentiation medium, consist-

ing of DMEM supplemented with 10% FBS, 100 nM dexamethasone (Sigma-Aldrich; Merck KGaA), 10 nM β-glycerophosphate (Sigma- Aldrich; Merck KGaA), and 50 μg/ml ascorbic acid (Sigma- Aldrich; Merck KGaA). Cells were cultured in the osteogenic differentiation medium for 21 days and the medium was changed every 3 days. Differentiated cells were analyzed by alizarin red staining and observed under an inverted microscope (Nikon Eclipse Ts2R, Japan).

2.5 Cell viability and proliferation assays

UC- hMSCs were seeded at 1×10^3 cells/well in 96-well plates (Costa, Corning, USA) containing 100 μl of 10% Fetal bovine serum (FBS) (GibcoBRL, USA) in growth medium. After 24 hours, cells were treated with 0.01-50 μM Andrographolide (Sigma-Aldrich, USA) for 24 -120 hours. The cell viability was measured by colorimetric MTT assay. Cell viability (%) was calculated against untreated control cells. The IC50 values were calculated according to dose-dependent curves. Cell proliferation was measured using a bromodeoxyuridine (BrdU) cell proliferation assay kit (Sigma-Aldrich; Merck KGaA). The measurements were performed in triplicate.

2.6 Statistical analysis

Data are presented as the mean ± standard error of the mean (SEM). Group comparisons were made by one-way analysis of variance (ANOVA). Multiple comparisons between the groups were performed using the Student-Newman-Keuls method. A value of $p < 0.05$ was considered to indicate a statistically significant difference.




Fig. 1. The morphology of UC-MSCs.

3. Results and Discussion

3.1 Morphology of UC-hMSCs

UC-hMSCs have been considered as an excellent primitive source of noncontroversial stem cells [10]; as such, UC-hMSCs were used for this study. Firstly, cells were isolated and cultured in difference passage (passage 2 and passage 6). The UC-hMSCs exhibited fibroblast-like morphology in the growth medium which could attach, spread, and display a spindle-shaped morphology on the plastic surface of the tissue culture flasks (Fig. 1). The UC-hMSCs were successfully isolated and expanded.

3.2 Immunophenotype of UC-hMSCs

According to the standard definition of MSCs [6], the expression of MSC surface markers was assessed. As expected, the UC-hMSCs expressed typical hMSC surface markers including CD73, CD90, and CD105 but they did not express hematopoietic markers including CD34 and CD45 (Fig. 2).

3.3 Differentiation potential of UC-hMSCs

Under certain conditions, MSCs can be multipotent, meaning that they can differentiate into multiple different types of cells. After the UC-MSCs were cultured under adipogenic conditions for 4 weeks, the cells' shape changed from spindle to large and round, indicating the accumulation of lipid droplets in their cytoplasm (Fig. 3A). In contrast, lipid droplets were not found in the control cultured cells. Calcium deposits are an indication of successful *in vitro* bone formation, which can be specifically verified using alizarin red staining [14]. In this study, calcium depositions were detected in the osteogenic treated cells after 3 weeks (Fig. 3B), these deposits were not found in the control cells. These results suggest that UC-hMSCs have the potential to differentiate into adipocyte and osteoblast cells upon proper stimulation.




Fig. 2. The expressions of typical cell surface markers of mesenchymal stem cells.




Fig. 3. Differentiation potential of UC-hMSCs. (A) Representative images of oil red O staining of UC-hMSCs cultured in adipogenic differentiation medium compared to growth control for 28 days. (B) Representative images of alizarin red staining of UC-MSCs cultured in osteogenic differentiation medium compared to growth control for 21 days. Scale bar, 100 μ m.

Table 2. Effect of Andrographolide (AP) on UC-hMSCs cell viability. Data are expressed as percent cell survival compared to untreated control cells at each time point.

AP (μM)	Time (h)				
	24	48	72	96	120
Control	100.00 ± 0.00	100.00 ± 0.00	100.00 ± 0.00	100.00 ± 0.00	100.00 ± 0.00
0.01	121.64 ± 4.57**	112.47 ± 0.76*	115.94 ± 4.07*	109.78 ± 1.43	108.52 ± 2.04
0.1	130.98 ± 4.69**	117.57 ± 1.78**	123.67 ± 1.81**	113.19 ± 1.24*	117.13 ± 1.66*
1	132.78 ± 2.79**	122.58 ± 2.25**	128.41 ± 2.08**	125.32 ± 1.77**	134.50 ± 3.06**
2	133.00 ± 3.20**	123.38 ± 3.11**	138.05 ± 3.19**	122.70 ± 2.38**	126.05 ± 1.91**
2.5	131.39 ± 3.55**	121.59 ± 1.33*	132.08 ± 3.79**	118.89 ± 3.48	123.12 ± 2.60**
5	116.01 ± 4.44**	112.79 ± 0.66*	124.03 ± 2.74**	108.06 ± 3.16	109.69 ± 0.85
10	101.26 ± 2.56	98.88 ± 0.83	109.18 ± 2.20	92.70 ± 1.08	89.53 ± 1.76**
20	83.86 ± 2.08**	77.36 ± 1.26**	75.51 ± 3.08**	68.25 ± 3.27**	58.47 ± 4.51**
50	49.89 ± 1.94**	31.84 ± 3.28**	43.65 ± 1.48**	26.64 ± 1.06**	16.53 ± 3.67**
IC 50 (μM)	50.56 ± 4.44	40.54 ± 1.92	37.28 ± 4.05	32.63 ± 3.57	24.90 ± 3.06

Each value is mean ± SEM. * $p < 0.05$ and ** $p < 0.01$ significant difference when compared to untreated control cells.




Fig. 4. Effect of Andrographolide on UC-hMSC proliferation. Data are expressed as mean ± SEM from 3 independent experiments. * $P < 0.05$, ** $P < 0.01$ significantly different from untreated control cells.

From MSCs characterization, the UC-hMSCs displayed a fibroblast-like morphology, typically positive for CD73, CD90, and CD105 and can develop in to adipocyte and osteoblast cells which meets the criteria of the International Society for Cellular Therapy. Therefore, UC-hMSCs were used for this study.

3.4 Effect of Andrographolide on UC-hMSC viability and proliferation

Table 1 shows cell viability of the UC-hMSCs treated with Andrographolide in

growth medium compared to control group for 24-120 hours. The cell viability of UC-hMSCs treated with 0.1-2.5 μM Andrographolide were significantly larger than the control group ($p < 0.05$ and $p < 0.01$). In contrast, cell viability of UC-hMSCs treated with 20-50 μM Andrographolide were significantly lower than the control group ($p < 0.05$ and $p < 0.01$). The IC₅₀ of Andrographolide on UC-hMSCs at 24 hours is more than 50 μM, and IC₅₀ of Andrographolide on UC-hMSCs at 48, 72, 96 and 120 hours are $40.54 ± 1.92$, $37.28 ± 4.05$,

32.63 ± 3.57, and 24.90 ± 3.06, respectively. This difference also reflected an increase in cell proliferation which was confirmed by BrdU assay (Fig 4.). Cell proliferation of UC-hMSCs cultured in growth medium treated with 0.1-5 µM Andrographolide was significantly increased after treatment for 24, 48, 72, 96, and 120 hours compared to the control group ($p < 0.05$ and $p < 0.01$). These results indicate that Andrographolide has a proliferative effect on UC-hMSCs.

Several studies have reported that the reduction of MSC growth and differentiation is related to excessive production of free radicals [15]. Increased levels of reactive oxygen radicals cause the increase of toxic pro-inflammatory cytokines that subsequently affect many cellular processes, including cell adhesion, migration, proliferation, and cellular senescence in MSCs [16-17]. In this study, it was demonstrated that Andrographolide increases cell viability and proliferation of UC-hMSCs. These effects may result from the anti-inflammatory and anti-oxidative properties of Andrographolide [11]. A previous study demonstrated that Andrographolide exerted an anti-inflammatory effect by inhibiting the activation of the NF-κB/MAPK signaling pathway and the induction of proinflammatory cytokines [18]. Moreover, Andrographolide downregulated free radical production to prevent neuronal cell degeneration [19] and also suppressed ROS-mediated NF-κB signaling [20]. However, the exact mechanisms involved in the cytoprotective and proliferative effects of Andrographolide on UC-hMSCs needs further investigation.

4. Conclusion

The current work is the first report demonstrating the proliferative effect of Andrographolide on UC-hMSCs in culture. These results suggest the potential opportunities of Andrographolide for further development as an alternative agent to increase the number of MSCs for use in

therapeutic applications of degenerative disease treatment.

Acknowledgements

This study was supported by Thammasat University Research Fund under the TU research Scholar, the Program Management Unit (Brain Power, Manpower), Office of National Higher Education Science Research and Innovation Policy Council, Thailand, and Center of Excellence in Stem Cell Research, Thammasat University.

References

- [1] Ganguly P, El-Jawhari JJ, Giannoudis PV, Burska AN, Ponchel F, Jones EA. Age-related Changes in Bone Marrow Mesenchymal Stromal Cells: A Potential Impact on Osteoporosis and Osteoarthritis Development. *Cell Transplant.* 2017;26(9):1520-9.
- [2] Friedenstein AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. *Cell and tissue kinetics.* 1987;20[3]:263-72.
- [3] Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue engineering.* 2001;7[2]:211-28.
- [4] Iwatani S, Shono A, Yoshida M, Yamana K, Thwin KKM, Kuroda J, et al. Involvement of WNT Signaling in the Regulation of Gestational Age-Dependent Umbilical Cord-Derived Mesenchymal Stem Cell Proliferation. *Stem cells international.* 2017;2017:8749751.
- [5] Pelekanos RA, Sardesai VS, Futrega K, Lott WB, Kuhn M, Doran MR. Isolation and Expansion of Mesenchymal Stem/Stromal Cells Derived from Human Placenta Tissue. *Journal of visualized experiments : JoVE.* 2016(112).
- [6] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D,

- et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8[4]:315-7.
- [7] Satija NK, Singh VK, Verma YK, Gupta P, Sharma S, Afrin F, et al. Mesenchymal stem cell-based therapy: a new paradigm in regenerative medicine. *Journal of cellular and molecular medicine*. 2009;13(11-12):4385-402.
- [8] Rastegar F, Shenaq D, Huang J, Zhang W, Zhang BQ, He BC, et al. Mesenchymal stem cells: Molecular characteristics and clinical applications. *World journal of stem cells*. 2010;2[4]:67-80.
- [9] Tormin A, Brune JC, Olsson E, Valcich J, Neuman U, Olofsson T, et al. Characterization of bone marrow-derived mesenchymal stromal cells (MSC) based on gene expression profiling of functionally defined MSC subsets. *Cytotherapy*. 2009;11[2]:114-28.
- [10] Oppliger B, Joerger- Messerli MS, Simillion C, Mueller M, Surbek DV, Schoeberlein A. Mesenchymal stromal cells from umbilical cord Wharton's jelly trigger oligodendroglial differentiation in neural progenitor cells through cell-to-cell contact. *Cytotherapy*. 2017;19(7):829-38.
- [11] Abu-Ghefreh AaA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide. *International Immunopharmacology*. 2009;9[3]:313-8.
- [12] Ajaya Kumar R, Sridevi K, Vijaya Kumar N, Nanduri S, Rajagopal S. Anticancer and immunostimulatory compounds from *Andrographis paniculata*. *Journal of Ethnopharmacology*. 2004;92[2]:291-5.
- [13] Jayakumar T, Hsieh C-Y, Lee J-J, Sheu J-R. Experimental and Clinical Pharmacology of *Andrographis paniculata* and Its Major Bioactive Phytoconstituent Andrographolide. Evidence-based Complementary and Alternative Medicine: eCAM. 2013;2013:846740.
- [14] Paul H, Reginato AJ, Schumacher HR. Alizarin red S staining as a screening test to detect calcium compounds in synovial fluid. *Arthritis and rheumatism*. 1983;26[2]:191-200.
- [15] Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. *Bone*. 2003;33[6]:919-26.
- [16] Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *The international journal of biochemistry & cell biology*. 2007;39[1]:44-84.
- [17] Yagi H, Tan J, Tuan RS. Polyphenols suppress hydrogen peroxide-induced oxidative stress in human bone-marrow derived mesenchymal stem cells. *Journal of cellular biochemistry*. 2013;114[5]:1163-73.
- [18] Li Y, He S, Tang J, Ding N, Chu X, Cheng L, et al. Andrographolide Inhibits Inflammatory Cytokines Secretion in LPS-Stimulated RAW264.7 Cells through Suppression of NF- κ B/ MAPK Signaling Pathway. *Evid Based Complement Alternat Med*. 2017;2017:8248142.
- [19] Sani D, Ramli N, Kirby B, Sumon S, Basri H, Stanslas J. Andrographolide downregulates pro-inflammatory cytokines and free radical productions to prevent dopaminergic neuro-degeneration induced by lipopolysaccharide (1143.16). *The FASEB Journal*. 2014;28(1_supplement):1143.16.
- [20] Peng S, Gao J, Liu W, Jiang C, Yang X, Sun Y, et al. Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF- κ B signaling and NLRP3 inflammasome activation. *Oncotarget*. 2016;7(49):80262-74.